How normal-appearing vitiligo skin keeps its pigment: PD-1 and regulatory T cells restrain disease-ready CD8 T cells
How an engineered CD40 antibody, injected into tumors, builds the immune structures that drive whole-body cancer responses
Can a single gut bacterium rescue failing immunotherapy? F. prausnitzii strain EXL01 restores checkpoint-inhibitor response
Can a simple blood test predict who responds to immunotherapy? Circulating L-arginine tracks checkpoint-inhibitor survival
Does acetaminophen blunt cancer immunotherapy? Plasma evidence links paracetamol to worse checkpoint-inhibitor outcomes
Why IDO1 inhibitors fell short in cancer immunotherapy — and what comes next for tryptophan targeting
How plasma LIF predicts immune-checkpoint blockade resistance and a TLS-poor tumor microenvironment
How BAF/PBAF chromatin-remodeler mutations predict better checkpoint-inhibitor outcomes — and point toward combination strategies
Why melanoma escapes BRAF inhibitors — the AhR transcription factor behind resistance and relapse
